<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-376
Date of Submission: 2025-01-10

This report was submitted by a Physician from Davis-Tate Medical Center concerning patient ANON-PX-5173. The subject is a 32-year-old male with a significant medical history including type 2 diabetes, asthma, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 442mg, initiated on 2024-12-08 for Neuropathic pain and discontinued on 2025-01-07.

On approximately 2024-12-16, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Headache, Vomiting, Diarrhea. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Go family leader final. Charge enjoy every teach well news region. Low toward throughout actually. Government reason chair rate lay size.</data>
report_id: ADR-2025-376
report_date: '2025-01-10'
patient_details:
  patient_id: ANON-PX-5173
  gender: Male
  relevant_history:
  - type 2 diabetes
  - asthma
  - migraines
  age_at_reaction: 32
suspected_drugs:
- drug_name: Gabapentin
  dosage: 442mg
  route_of_administration: Oral
  start_date: '2024-12-08'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-01-07'
adverse_reactions:
- symptom_name: Hepatotoxicity
  onset_date: '2024-12-16'
  severity: Severe
  outcome: Recovered
  intervention_required: true
- symptom_name: Headache
  onset_date: '2024-12-16'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: false
- symptom_name: Vomiting
  onset_date: '2024-12-16'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Diarrhea
  onset_date: '2024-12-16'
  severity: Severe
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
  naranjo_score: 8
reporting_facility: Davis-Tate Medical Center
reporter_type: Physician
notes: Go family leader final. Charge enjoy every teach well news region. Low toward
  throughout actually. Government reason chair rate lay size.
